On the call-it-what-it-is basis the filings demand, here is Moderna as its annual report describes it. In its 10-K for fiscal 2019, filed February 27, 2020, the company presents itself as a clinical-stage biotechnology business built around messenger-RNA technology, with a pipeline that is wide but, for now, early.
The disclosed programs read like a tour of the platform’s ambitions rather than a commercial portfolio. The 10-K lists Phase 1 vaccine candidates including an H10N8 influenza vaccine (mRNA-1440), an H7N9 influenza vaccine (mRNA-1851), a respiratory syncytial virus vaccine (mRNA-1777) and a Chikungunya vaccine (mRNA-1388), alongside a cytomegalovirus (CMV) program and an Epstein-Barr virus vaccine (mRNA-1189) described in the filing as seeking to address a virus implicated in mononucleosis and other conditions.
What the document does not contain is a marketed product. As of this filing, Moderna is pre-revenue in the commercial sense — its model is to validate one delivery-and-expression platform across many indications, then advance the most promising candidates. That is the fundamentals-first read: the value here is optionality on a technology, not cash flow from a drug.
For an investor treating biotech as an asset class, the 2019 10-K is a baseline document. It frames the company before any single program has carried the platform to approval, which is precisely why it is worth reading on its own terms — a snapshot of the bet as it stood at the start of 2020, untouched by what any given program might later become.
Every figure above is drawn from the company's primary SEC filing — surfaced through EdgarBeast, the SEC filing data API and evidence index — and verifiable against the filing on sec.gov.